Resistance Profile, Terbinafine Resistance Screening and MALDI-TOF MS Identification of the Emerging Pathogen Trichophyton indotineae.


Journal

Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 01 12 2023
accepted: 25 01 2024
medline: 18 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

The emerging pathogen Trichophyton indotineae, often resistant to terbinafine (TRB), is known to cause severe dermatophytoses such as tinea corporis and tinea cruris. In order to achieve successful treatment for these infections, insight in the resistance profile of T. indotineae strains and rapid, reliable identification is necessary. In this research, a screening medium was tested on T. indotineae strains (n = 20) as an indication tool of TRB resistance. The obtained results were confirmed by antifungal susceptibility testing (AST) for TRB following the in vitro broth microdilution reference method. Additionally, AST was performed for eight other antifungal drugs: fluconazole, itraconazole, voriconazole, ketoconazole, griseofulvin, ciclopirox olamine, naftifine and amorolfine. Forty-five percent of the strains were confirmed to be resistant to terbinafine. The TRB resistant strains showed elevated minimal inhibitory concentration values for naftifine and amorolfine as well. DNA sequencing of the squalene epoxidase-encoding gene showed that TRB resistance was a consequence of missense point mutations in this gene, which led to amino acid substitutions F397L or L393F. MALDI-TOF MS was used as a quick, accurate identification tool for T. indotineae, as it can be challenging to distinguish it from closely related species such as Trichophyton mentagrophytes or Trichophyton interdigitale using morphological characteristics. While MALDI-TOF MS could reliably identify ≥ 95% of the T. indotineae strains (depending on the spectral library), it could not be used to successfully distinguish TRB susceptible from TRB resistant strains.

Identifiants

pubmed: 38483637
doi: 10.1007/s11046-024-00835-4
pii: 10.1007/s11046-024-00835-4
pmc: PMC10940462
doi:

Substances chimiques

Terbinafine G7RIW8S0XP
Antifungal Agents 0
naftifine 4FB1TON47A
Allylamine 48G762T011

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29

Informations de copyright

© 2024. The Author(s).

Références

J Antimicrob Chemother. 2020 Jul 1;75(7):1807-1819
pubmed: 32303059
Emerg Infect Dis. 2022 Jan;28(1):229-233
pubmed: 34932456
Mycoses. 2018 Jul;61(7):477-484
pubmed: 29577447
J Fungi (Basel). 2021 Nov 18;7(11):
pubmed: 34829270
J Clin Microbiol. 2017 Sep;55(9):2661-2670
pubmed: 28637907
Dermatology. 1992;184 Suppl 1:3-7
pubmed: 1550968
PLoS One. 2011;6(12):e28425
pubmed: 22194834
Fungal Genet Biol. 2019 Dec;133:103266
pubmed: 31491507
J Fungi (Basel). 2020 Oct 05;6(4):
pubmed: 33027904
J Fungi (Basel). 2022 Jul 21;8(7):
pubmed: 35887512
Antimicrob Agents Chemother. 2003 Jan;47(1):82-6
pubmed: 12499173
Acta Microbiol Immunol Hung. 2007 Sep;54(3):201-35
pubmed: 17896473
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 30021820
Mycopathologia. 2021 Jun;186(3):315-326
pubmed: 33847867
Mycopathologia. 2017 Feb;182(1-2):183-192
pubmed: 27734185
Antimicrob Agents Chemother. 2014 May;58(5):2825-9
pubmed: 24614379
Clin Microbiol Infect. 2021 Jan;27(1):55-60
pubmed: 32916260
Rev Iberoam Micol. 1997 Jun;14(2):44-9
pubmed: 16854169
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28416557
J Fungi (Basel). 2022 Feb 23;8(3):
pubmed: 35330222
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530857
Mycoses. 2008 Sep;51 Suppl 4:2-15
pubmed: 18783559
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0005621
pubmed: 33972254
Clin Infect Dis. 2019 May 17;68(11):1791-1797
pubmed: 30204844
Clin Microbiol Rev. 1995 Apr;8(2):240-59
pubmed: 7621400
J Med Microbiol. 2009 Feb;58(Pt 2):163-168
pubmed: 19141731
J Fungi (Basel). 2022 Oct 19;8(10):
pubmed: 36294668
J Clin Microbiol. 2012 Jul;50(7):2479-83
pubmed: 22535984
Am Fam Physician. 2003 Jan 1;67(1):101-8
pubmed: 12537173
Mycoses. 2019 Apr;62(4):336-356
pubmed: 30561859
JAAD Int. 2020 Nov 30;2:22-27
pubmed: 34409349
Med Mycol. 2013 Jan;51(1):17-24
pubmed: 22574631
Mycopathologia. 2020 Dec;185(6):947-958
pubmed: 32449054
Int J Dermatol. 2023 Jul;62(7):857-861
pubmed: 35867962
J Antimicrob Chemother. 2022 Mar 31;77(4):1212-1213
pubmed: 35075481
Front Microbiol. 2018 Oct 30;9:2577
pubmed: 30425693
J Clin Microbiol. 2013 Sep;51(9):2964-9
pubmed: 23824764

Auteurs

Roelke De Paepe (R)

Mycology and Aerobiology Department, Sciensano, 1050, Brussels, Belgium. roelke.depaepe@sciensano.be.

Anne-Cécile Normand (AC)

Parasitology/Mycology Department, AP-HP, Hôpitaux de Paris, 75013, Paris, France.

Silke Uhrlaß (S)

Labopart Medical Laboratories Leipzig-Mölbis, 04571, Rötha OT Mölbis, Germany.

Pietro Nenoff (P)

Labopart Medical Laboratories Leipzig-Mölbis, 04571, Rötha OT Mölbis, Germany.

Renaud Piarroux (R)

Parasitology/Mycology Department, AP-HP, Hôpitaux de Paris, 75013, Paris, France.

Ann Packeu (A)

Mycology and Aerobiology Department, Sciensano, 1050, Brussels, Belgium.
BCCM/IHEM Fungal Collection, Mycology and Aerobiology Section, Sciensano, 1050, Brussels, Belgium.

Articles similaires

Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol
Vibrio Whole Genome Sequencing Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Genome, Bacterial Water Microbiology

Naturally derived 3-aminoquinuclidine salts as new promising therapeutic agents.

Doris Crnčević, Alma Ramić, Andreja Radman Kastelic et al.
1.00
Humans Microbial Sensitivity Tests Anti-Bacterial Agents Biofilms Quinuclidines

Classifications MeSH